The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Oxford Myeloma Workshop 2025 | Engineering complex human pre-clinical models and their applications for myeloma
In this video, Abdullah Khan, BSc (Hons), MRes, PhD, MRC Weatherall Institute of Molecular Medicine, Oxford, UK, discusses the engineering of complex human pre-clinical models and their applications for multiple myeloma (MM). Dr Khan highlights the need for physiologically complex human models of the bone marrow to study disease progression and develop more effective treatments. He also notes that maintaining patient samples for long-term studies is a significant challenge but hopes that this can be addressed in the coming years. This interview took place at the 5th Oxford Myeloma Workshop in Oxford, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
We’ve been working for the last few years in trying to build more physiologically complex human models of the bone marrow. The idea being that there’s a need for human systems that capture the complexity of the whole organ to enable more translational research. And that’s been our focus now for five or six years, which makes me feel a bit old.
Essentially, we started off working in the context of myeloid cancers and increasingly as we build more niche complexity, the next big question for us was whether we can use this to study myeloma, which is a disease that has very critical elements of the microenvironment involved in its progression and is a very real need for more effective treatments...
We’ve been working for the last few years in trying to build more physiologically complex human models of the bone marrow. The idea being that there’s a need for human systems that capture the complexity of the whole organ to enable more translational research. And that’s been our focus now for five or six years, which makes me feel a bit old.
Essentially, we started off working in the context of myeloid cancers and increasingly as we build more niche complexity, the next big question for us was whether we can use this to study myeloma, which is a disease that has very critical elements of the microenvironment involved in its progression and is a very real need for more effective treatments. And we think that human preclinical models are a way forward to those treatments and to meet that need.
I think the major challenge is whether we can maintain patient samples for long enough to be able to look at acquired resistance to therapies and clonal evolution and mutations. I think that’s a major need not only in myeloma but also across other blood cancer types. And hopefully that’s something we can address in the coming years.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consultancy: Alethiomics, VAI.
